|  ≥ KDIGO 3 AKI | P-value | |
---|---|---|---|
Yes, n = 41 | No, n = 154 | ||
Age, years (SD) | 71.4 (12.2) | 74.4 (13.8) | 0.138 |
Sex | 0.421 | ||
Male | 26 (63.4%) | 112 (72.7%) | Â |
Female | 15 (36.6%) | 42 (27.3%) | Â |
BMI (SD) | 22.2 (5.6) | 22.3 (4.3) | 0.788 |
Smoking | 15 (36.6%) | 63 (40.9%) | 0.363 |
Comorbidities | Â | ||
Diabetes | 12 (29.5%) | 45 (29.2%) | 0.958 |
Malignancies | 10 (24.4%) | 23 (14.9%) | 0.243 |
Renal insufficiency | 6 (14.6%) | 15 (9.7%) | 0.211 |
Chronic liver diseases | 3 (7.3%) | 13 (8.4%) | 1.000 |
Heart failure | 3 (7.8%) | 14 (9.1%) | 0.767 |
CR-GNB culture sources | 0.035 | ||
Respiratory specimens | 39 (95.1%) | 118 (76.6%) | Â |
Urine | 0 | 10 (6.5%) | Â |
Blood | 2 (4.9%) | 9 (5.8%) | Â |
Othersb | 0 | 17 (11.0%) | Â |
CR-GNB species | 0.229 | ||
CRAB | 34 (82.9) | 107 (69.5%) | Â |
CRE | 6 (14.6%) | 39 (25.3%) | Â |
CRPA | 1 (2.4%) | 8 (5.2%) | Â |
Laboratory results (Mean, SD) | Â | ||
Leukocytes (× 109 per L) | 11.5 (9.9) | 13.7 (8.8) | 0.183 |
CRP (mg/dL) | 10.5 (10.0) | 9.8 (5.6) | 0.555 |
Albumin level | 2.8 (2.5–3.1) | 2.7 (2.4–3.0) | 0.217 |
Concomitant nephrotoxins | Â | ||
Aminoglycoside | 5 (12.2%) | 17 (11.0%) | 0.835 |
Vancomycin | 8 (19.5%) | 12 (7.8%) | 0.028 |
Intravenous contrast agent | 9 (22%) | 30 (19.5%) | 0.725 |
Disease severities | Â | ||
APACHEII scores (median, IQ R)c | 23 (18–31) | 25 (20–30) | 0.454 |
Respiratory failured | 40 (97.6%) | 135 (87.7%) | 0.081 |
Septic shockd | 22 (53.7) | 39 (25.3%) | 0.001 |
Colistin treatment | Â | ||
Daily dose (MIU) (median, IQR) | 8 (7.4–10) | 8 (4–10) | 0.036 |
Treatment duration (days) (median, IQR) | 7 (4–11) | 7 (4–12) | 0.403 |
Accumulated dose (MIU) (median, IQR) | 46.5 (30.5–87.2) | 48 (24–80) | 0.594 |
Inappropriate colistin dose | 9 (22.0%) | 14 (9.1%) | 0.023 |